Page 151 - CW E-Magazine (7-11-2023)

Pharmaceuticals

“India has been a focus market for The company is looking at inor- and Managing Director, Mr. G. V. Prasad,
us. We launched a direct-to-consumer ganic growth using a cash balance of said. “The growth was on account of
website for diabetes. This will be a Rs. 6,978-crore. “We delivered another growing momentum in our core portfolio,
future pillar for the company,” Mr. Agarwal quarter of strong results with highest ever Mayne integration, favourable move
said. The Indian market contributed sales and profi ts, driven by market share from foreign exchange which was partly
17 percent (Rs. 1,200-crore), registering a gains & momentum in our US generics offset by price erosion,” he added. Of the
year-on-year growth of 3 percent. “This business and robust growth in Europe. revenue of Rs. 1,200-crore in the quarter
growth was largely driven by pricing We are continuing to strengthen our from the emerging markets, Russia consti-
and new launches. The muted demand pipeline both organically and through tuted nearly half (Rs. 580-crore), which
was due to the weak acute season,” the business development to drive growth declined by 3 percent year on year owing
company said in a regulatory fi ling.. and create differentiation,” Co-Chairman to currency devaluation.

PRODUCT INNOVATION
IISER Bhopal develops clear, safe, biomedical adhesive

to repair injured tissues

A team of researchers at the Indian Such biodegradable and biocom- polymers have multiple amide groups
Institute of Science Education and Research patible adhesives fi nd applications in and thiol residues that lead to strong
(IISER), Bhopal, has developed a clear medicine, dentistry, drug delivery, and adhesion due to the formation of hydro-
synthetic biomedical adhesive that can tissue engineering. They are also used gen bonds and disulphide bonds. The
effectively seal and repair injured and dis- in orthopaedic procedures to enhance resulting adhesive layer is colourless
sected tissues. This adhesive, which is bio- bone repair and as an alternative to and transparent. The adhesive formula-
degradable and biocompatible, is capable sutures, staples, and wires, in wound tions developed by the IISER team will
of binding different surfaces such as tis- closures. The researchers used a mixture fi nd use in cosmetics and biological
sues, bones, eggshells, and wood, in both of oppositely-charged water-soluble applications. The researchers are working
air and underwater and requires no addi- polyelectrolytes known for their biode- towards optimising these adhesives for
tional crosslinking agents or metal ions. gradability and biocompatibility. These such real-life applications.
GOING STRONG
Cipla posts healthy Q2 net profi t on the back of India

and US operations

Mumbai-based Cipla posted robust Cipla’s Managing Director and Global prescription continues to outpace market
numbers for the three months ended Chief Executive Offi cer Mr. Umang growth while seasonal trends impacted
September 30, 2023, on the back of its Vohra made a distinction between the the consumer business for the quarter,”
performance in India and the US. company and promoter, adding that the company said. It’s North America
they had “not heard of anything, either segment saw quarterly revenue at $229-mn,
The company posted revenues of way.” There was anxiety as many things up 28 percent over the same period last
Rs. 6,678-crore for the second quarter depend on this decision, Mr. Vohra told year. The South Africa private market
(Q2), up 14.6 percent over last year’s mediapersons, adding that the Cipla’s grew at 12 percent in local currency
performance in the same period. It’s philosophy has always been to invest terms, in the period under review, the
profi t after tax for the period under in the future, and the reports were be- company said. Crediting the “exceptional
review stood at Rs. 1,131-crore, up 43 coming a “distraction” of sorts. set of results” to the core businesses
percent. The performance comes even across India, North America and South
as reports said Cipla promoters were Q2 performance Africa, Mr. Vohra said, “We reported
looking to offl oad equity in the company – On the operation’s front, Cipla saw our highest ever quarterly revenue with
something the company top man- a 10 percent growth in its “One India” EBITDA margins scaling up to 26 per-
agement have labelled as “speculation”. branded prescriptions and trade generics cent.” The company sits on net cash
Responding to queries on the reports, businesses, at Rs. 2,817-crore. “Branded of Rs. 5,850-crore.

Chemical Weekly November 7, 2023 151

Contents Index to Advertisers Index to Products Advertised